BioMedPartners
Overview
BioMedPartners is a European venture capital firm providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. BioMedPartners targets the entire industry with a special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Investment Focus
- Innovative technologies addressing significant medical needs
- Strong scientific and clinical evidence supporting product efficacy
- Experienced management teams with a clear vision for company growth
- Potential for significant impact in the healthcare sector
- Innovative technologies
- Strong management teams
- Scalable business models
- Potential for significant market impact
Portfolio Companies
Reach BioMedPartners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about BioMedPartners
What sectors does BioMedPartners invest in?
BioMedPartners invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Basel, Basel-Stadt, Switzerland. BioMedPartners is listed as a vc in the ConnectSafely investor database.
What stage does BioMedPartners invest at?
BioMedPartners backs companies at Early Stage, Series A, Series B and Growth, writing cheques of 1M - 10M.
Which regions does BioMedPartners invest in?
BioMedPartners invests across Germany, France, Italy, Switzerland, Luxembourg and Austria.
Who are the partners at BioMedPartners?
Team members listed for BioMedPartners include Stefan Fäs (CFO & Partner) and Thomas Möller (Managing General Partner).
What companies has BioMedPartners invested in?
BioMedPartners's portfolio includes Amal Therapeutics SA, Okairos AG, SuppreMol GmbH, Glycart Technology AG, ESBATech AG, Arpida AG, Santhera Pharmaceuticals AG and Evolva Holding AG.
How do I contact BioMedPartners?
BioMedPartners's contact details are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
